Shanghai Pharmaceutical (02607) terminates clinical trials and subsequent development of the I025-A R&D project

Zhitongcaijing · 2d ago

Zhitong Finance App News, Shanghai Pharmaceutical (02607) announced that in order to rationally allocate R&D resources and focus on advantageous R&D projects, the company decided to terminate clinical trials and subsequent development of I025-A R&D projects based on a comprehensive evaluation of factors such as future market value, business collaboration, and subsequent development investment of R&D projects.